WHAT: Rho, a full-service contract research organization (CRO), will provide valuable insight into the differences between the FDA’s Accelerated Approval, Breakthrough Therapy, Priority Review and Fast Track designations through a free webinar. Understanding the requirements and potential benefits of each mechanism for expedited development and approval will help sponsors make informed decisions about the best choice for their drug development programs.
In this webinar, Dr. David Shoemaker, senior vice president, R&D, Rho, will explain the differences between these programs, describe strategies to determine which program may be right for your drug trial, and discuss FDA expectations and requirements for each pathway.
WHO: Dr. David Shoemaker
WHEN: Tuesday, October 20, 2015
1 pm ET/10 am PT
Duration: 60 minutes
Webinar Registration: http://bit.ly/1VBTf1n
DETAILS: For media inquiries, please contact Bernadette Miller at Largemouth Communications,
(703) 297-5992, bernadette@largemouthpr.com.
ABOUT:
Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 31 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.
Help employers find you! Check out all the jobs and post your resume.
